Bank Of New York Mellon Corp 89bio, Inc. Transaction History
Bank Of New York Mellon Corp
- $529 Trillion
- Q2 2025
A detailed history of Bank Of New York Mellon Corp transactions in 89bio, Inc. stock. As of the latest transaction made, Bank Of New York Mellon Corp holds 349,572 shares of ETNB stock, worth $5.19 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
349,572
Previous 309,916
12.8%
Holding current value
$5.19 Million
Previous $2.25 Billion
52.36%
% of portfolio
0.0%
Previous 0.0%
Shares
21 transactions
Others Institutions Holding ETNB
# of Institutions
212Shares Held
161MCall Options Held
299KPut Options Held
1.61M-
Janus Henderson Group PLC London, X020.8MShares$308 Million0.11% of portfolio
-
Ra Capital Management, L.P. Boston, MA19.9MShares$295 Million4.27% of portfolio
-
Suvretta Capital Management, LLC New York, NY14.2MShares$211 Million4.8% of portfolio
-
Deep Track Capital, LP Greenwich, CT9.5MShares$141 Million3.31% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.24MShares$122 Million0.0% of portfolio
About 89bio, Inc.
- Ticker ETNB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,484,500
- Market Cap $690M
- Description
- 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...